181585-07-9

Basic information

• Product Name: 3-broMo-5-(2-Methoxyethoxy)pyridine
• Synonyms: 3-broMo-5-(2-Methoxyethoxy)pyridine
• CAS NO: 181585-07-9
• Molecular Formula: C₈H₁₀BrNO₂
• Molecular Weight: 232.0745
• Mol File: 181585-07-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-broMo-5-(2-Methoxyethoxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-broMo-5-(2-Methoxyethoxy)pyridine(181585-07-9)
• EPA Substance Registry System: 3-broMo-5-(2-Methoxyethoxy)pyridine(181585-07-9)

Safety Data

• Hazardous Substances Data: 181585-07-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-(2-methoxyethoxy)pyridine is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-bromo-5-(2-methoxyethoxy)pyridine serves as an intermediate for the production of agrochemicals, such as pesticides and herbicides, that can help protect crops from pests and diseases.
Used in Chemical Research:
3-Bromo-5-(2-methoxyethoxy)pyridine is also utilized in chemical research for studying its properties and reactivity. This knowledge can contribute to the advancement of organic chemistry and the development of new synthetic methods.
Used in Production of Other Organic Compounds:
Due to its unique structure, 3-bromo-5-(2-methoxyethoxy)pyridine is employed in the production of other organic compounds, expanding its applications in various chemical processes and industries.
It is important to handle 3-bromo-5-(2-methoxyethoxy)pyridine with caution, as it may pose health and environmental hazards. Proper safety measures should be taken during its synthesis, storage, and use to minimize potential risks.

Upstream product

• 625-92-3 3,5-dibromopyridine 
• 109-86-4 2-methoxy-ethanol 
• 74115-13-2 5-bromopyridine-3-ol 
• 6482-24-2 2-Bromoethyl methyl ether 

Downstream Products

• 1010104-34-3 5-(2-methoxyethoxy)-3-pyridineboronic acid pinacol ester 
• 1462279-11-3 1,4-bis(5-(2-methoxyethoxy)-pyridine-3-yl)benzene 
• 1383744-66-8 C₂₁H₂₃F₂N₅O₄S 

Relevant articles and documents

Structure and properties of 3-(Diethylboryl)pyridines

3-(Diethylboryl)pyridine (1a), a versatile starting material for the preparation of arylpyridines, is notable for its stability under ambient conditions, in spite of little steric hindrance on the boron atom. 1H and 13C spectra of 1a indicated that the boryl group does not act as a mere π-acceptor and that the boron atom is shielded by ca. 50 ppm even when compared with trivalent boron atoms conjugated with the π-donor. A single-crystal X-ray crystallographic study for 1a revealed formation of a cyclic-tetramer with a void via the intermolecular boron-nitrogen coordination bond. Vapor pressure osmometry in various solvents suggested that 1a comprises the tetramer in these solutions. In order to know the actual structure, synthesis of 3-(2-methoxyethoxy)-5-(diethylboryl)pyridine (1b) and its scrambling experiment with 1a were carried out. Heating at 100 °C for 24 h was required to attain the equilibrium of the scrambling of the component molecules in the tetramers. This means that 3-(diethylboryl)pyridines 1a and 1b comprise the rigid cyclic-tetramer in solution at ambient temperature. Compound 1b is stable in aerated tetrahydrofuran containing up to 33 % water.

NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A,X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A, X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

Highly fluorescent M2L4 molecular capsules with anthracene shells

M2L4 molecular capsules self-assembled from M(ii) ions (where M = Zn, Ni, and Pd) and bent bidentate ligands constructed from anthracene fluorophores. The Ni(ii) and Zn(ii) capsules exhibited weak to strong blue emission unlike traditional Pd(ii) cages and capsules. The Royal Society of Chemistry 2011.

FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE

The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c] quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H- imidazo[4,5-c] quinofinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c] quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H- imidazo[4,5-c] quinolinone derivatives; and a process for the preparation of the novel 1H- imidazo[4,5-c] quinolinone derivatives.

1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to the use of 1 H-imidazo[4,5-c]quinolinone compounds and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1 H-imidazo[4,5-c]quinolinone compounds for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1 H-imidazo[4,5-c]quinolinone compounds to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1 H-imidazo[4,5-c]quinolinone compounds, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H-imidazo[4,5-c]quinolinone compounds; and a process for the preparation of the novel 1 H-imidazo[4,5-c]quinolinone compounds.

HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS

The present invention describes tetracyclic compounds of formula (IA) or (IB), wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and wa

PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES

A compound of Formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the groups R1-R6 and A are as defined in the specification.

PYRROLO ISOQUINOLINES AS KINASE INHIBITORS

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1, R2, R3, R7 and X are as defined in the specification.